Trial Profile

ACCORD 2: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID 19 in Hospitalised Patients

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 26 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Acalabrutinib (Primary) ; Bemcentinib (Primary) ; Tozorakimab (Primary) ; Zilucoplan (Primary) ; Dexamethasone; Heparin; Olitigaltin
Indications COVID 2019 infections
Focus Therapeutic Use
Acronyms ACCORD-2 COVID-19; ACCORD2

Most Recent Events

26 Apr 2022 Results presented in the BerGenBio Media Release.
26 Apr 2022 Primary endpoint has been met (clinical response by day 29 ),according to a BerGenBio media release.
13 Aug 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com